Global Blood's voxelotor a Breakthrough Therapy for sickle cell disease; shares ahead 19%

|About: Global Blood Therapeut... (GBT)|By:, SA News Editor

The FDA designates Global Blood Therapeutics' (GBT +19.2%) lead candidate voxelotor a Breakthrough Therapy for the treatment of sickle cell disease. It also has PRIME status in Europe.

Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.

Voxelotor is an oral once-daily therapy that works by increasing hemoglobin's affinity for oxygen.

Previously: Global Blood's late-stage study of SCD candidate voxelotor to continue as planned, enrollment expanded to adolescents; shares ahead 2% premarket (Nov. 13, 2017)

Subscribe for full text news in your inbox